|
|
|
|
|
|
Sponsored by: |
Avexa |
Information provided by: | Avexa |
ClinicalTrials.gov Identifier: | NCT00334659 |
The purpose of this study is to confirm that apricitabine does not induce any clinically significant effect upon electrocardiogram (ECG) parameters at doses consistent with the maximum exposure expected to occur in clinical practice.
Condition | Intervention | Phase |
HIV Infections |
Drug: apricitabine |
Phase I |
MedlinePlus related topics: | AIDS |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Active Control, Crossover Assignment, Safety Study |
Official Title: | A Double-Blind, Placebo-Controlled, Positive Controlled, Randomized, Crossover Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects |
Estimated Enrollment: | 48 |
Study Start Date: | June 2006 |
Estimated Study Completion Date: | August 2006 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | AVX-101 |
First Received: | June 6, 2006 |
Last Updated: | January 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00334659 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|